Cadila Pharmaceuticals and Aplagon entered a development agreement

| By | Cadila Pharmaceuticals, Drug Development
0
1740

Aplagon Oy, a pharmaceutical discovery and development company, based in Helsinki, Finland, and Cadila Pharmaceuticals Sweden AB today announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury.

Under the agreement, Cadila Pharmaceuticals Sweden AB together with its parent company Cadila Pharmaceuticals Limited, India will undertake formulation development and commercial-scale manufacturing of Aplagon’s APAC product. Aplagon and Cadila Pharmaceuticals will conduct multicentre, randomized Phase I/II and Phase II/III clinical studies in India in a selected first indication to prevent vascular intervention-related blood vessel occlusions. Following additional pre-clinical studies required in India, it is anticipated that the first Indian clinical trial will start recruiting in 2019.

APACs, which were discovered by Aplagon scientists, are heparin proteoglycan mimetics. These biologics are being developed as first-in-class treatments for unmet patient needs associated with the prevention and management of both the short- and long -term complications of vascular intervention-related blood vessel occlusions. In the first instance, Aplagon is pursuing the development of APACs for selected indications where no current treatments exist.

“We are excited to partner with Cadila Pharmaceuticals, one of the largest privately held pharmaceutical companies in India. This collaboration will leverage Cadila Pharmaceutical’s excellent manufacturing operations as well as clinical and commercialization capabilities to facilitate the development of APAC through large Phase I-III clinical studies in a cost-efficient and timely way. This is a true win-win partnership for both parties,” said Aki Prihti, CEO of Aplagon.

SOURCE: aplagon
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.